Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. Issue 1 (21st March 2013)
- Record Type:
- Journal Article
- Title:
- Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. Issue 1 (21st March 2013)
- Main Title:
- Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes
- Authors:
- Kadaba, Raghu
Birke, Hanna
Wang, Jun
Hooper, Steven
Andl, Claudia D
Di Maggio, Francesco
Soylu, Erdinc
Ghallab, Mohammed
Bor, Daniel
Froeling, Fieke EM
Bhattacharya, Satyajit
Rustgi, Anil K
Sahai, Erik
Chelala, Claude
Sasieni, Peter
Kocher, Hemant M - Abstract:
- <abstract abstract-type="main"> <title>Abstract</title> <p> <bold>Epithelial tissues have sparse stroma, in contrast to their corresponding tumours. The effect of cancer cells on stromal cells is well recognized. Increasingly, stromal components, such as endothelial and immune cells, are considered indispensable for cancer progression. The role of desmoplastic stroma, in contrast, is poorly understood. Targeting such cellular components within the tumour is attractive. Recent evidence strongly points towards a dynamic stromal cell participation in cancer progression that impacts patient prognosis. The role of specific desmoplastic stromal cells, such as stellate cells and myofibroblasts in pancreatic, oesophageal and skin cancers, was studied in bio‐engineered, physiomimetic organotypic cultures and by regression analysis. For pancreatic cancer, the maximal effect on increasing cancer cell proliferation and invasion, as well as decreasing cancer cell apoptosis, occurs when stromal (pancreatic stellate cells) cells constitute the majority of the cellular population (maximal effect at a stromal cell proportion of 0.66–0.83), accompanied by change in expression of key molecules such as E‐cadherin and <italic>β</italic>‐catenin. Gene‐expression microarrays, across three tumour types, indicate that stromal cells consistently and significantly alter global cancer cell functions such as cell cycle, cell–cell signalling, cell movement, cell death and inflammatory response. However,<abstract abstract-type="main"> <title>Abstract</title> <p> <bold>Epithelial tissues have sparse stroma, in contrast to their corresponding tumours. The effect of cancer cells on stromal cells is well recognized. Increasingly, stromal components, such as endothelial and immune cells, are considered indispensable for cancer progression. The role of desmoplastic stroma, in contrast, is poorly understood. Targeting such cellular components within the tumour is attractive. Recent evidence strongly points towards a dynamic stromal cell participation in cancer progression that impacts patient prognosis. The role of specific desmoplastic stromal cells, such as stellate cells and myofibroblasts in pancreatic, oesophageal and skin cancers, was studied in bio‐engineered, physiomimetic organotypic cultures and by regression analysis. For pancreatic cancer, the maximal effect on increasing cancer cell proliferation and invasion, as well as decreasing cancer cell apoptosis, occurs when stromal (pancreatic stellate cells) cells constitute the majority of the cellular population (maximal effect at a stromal cell proportion of 0.66–0.83), accompanied by change in expression of key molecules such as E‐cadherin and <italic>β</italic>‐catenin. Gene‐expression microarrays, across three tumour types, indicate that stromal cells consistently and significantly alter global cancer cell functions such as cell cycle, cell–cell signalling, cell movement, cell death and inflammatory response. However, these changes are mediated through cancer type‐specific alteration of expression, with very few common targets across tumour types. As highlighted by these <italic>in vitro</italic> data, the reciprocal relationship of E‐cadherin and polymeric immunoglobulin receptor (PIGR) expression in cancer cells could be shown, <italic>in vivo</italic>, to be dependent on the stromal content of human pancreatic cancer. These studies demonstrate that context‐specific cancer–stroma crosstalk requires to be precisely defined for effective therapeutic targeting. These data may be relevant to non‐malignant processes where epithelial cells interact with stromal cells, such as chronic inflammatory and fibrotic conditions. Copyright © 2013 Pathological Society of Great Britain and Ireland. Published by John Wiley &amp; Sons, Ltd.</bold> </p> </abstract> … (more)
- Is Part Of:
- Journal of pathology. Volume 230:Issue 1(2013)
- Journal:
- Journal of pathology
- Issue:
- Volume 230:Issue 1(2013)
- Issue Display:
- Volume 230, Issue 1 (2013)
- Year:
- 2013
- Volume:
- 230
- Issue:
- 1
- Issue Sort Value:
- 2013-0230-0001-0000
- Page Start:
- 107
- Page End:
- 117
- Publication Date:
- 2013-03-21
- Subjects:
- Pathology -- Periodicals
616.07 - Journal URLs:
- http://onlinelibrary.wiley.com/ ↗
- DOI:
- 10.1002/path.4172 ↗
- Languages:
- English
- ISSNs:
- 0022-3417
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5029.900000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4146.xml